Full-Time
Develops monoclonal antibodies for infectious diseases
$242k - $329.5k/yr
Expert
San Francisco, CA, USA
This is an on-site position in our San Francisco Headquarters.
Upload your resume to see how it matches 3 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Vir Biotechnology develops treatments for infectious diseases by leveraging the immune system. They use a proprietary monoclonal antibody platform combined with machine learning to create a database of human antibodies, which helps in designing effective medicines. Their pipeline includes candidates for hepatitis B, HIV, and various viruses like influenza and COVID-19. Vir stands out through its collaborations with industry leaders and its commitment to addressing unmet medical needs.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Comprehensive healthcare coverage
Employer matched 401(k)
Employee stock purchase plan
Childcare assistance
Tuition reimbursement
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Moreover, Vir Biotechnology has entered into a significant licensing agreement with Amunix Pharmaceuticals, Inc., a Sanofi company.
Vir Biotechnology to cut 140 jobs in restructuring to focus on hepatitis drug development.
Vir Biotechnology, Inc. (NASDAQ:VIR) just released its quarterly report and things are looking bullish.
Vir Biotechnology Inc. (NASDAQ:VIR) announced Monday that Executive Vice President and Chief Financial Officer Sung Lee will resign from his position effective May 3, 2024.